Lipocine (NASDAQ:LPCN) Rating Increased to Hold at Wall Street Zen

Lipocine (NASDAQ:LPCN) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.

LPCN has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target (up from $7.00) on shares of Lipocine in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Lipocine Stock Performance

Shares of NASDAQ:LPCN opened at $7.15 on Friday. Lipocine has a twelve month low of $2.52 and a twelve month high of $12.37. The firm has a market cap of $52.20 million, a PE ratio of -4.24 and a beta of 0.98. The business has a fifty day moving average of $9.06 and a 200-day moving average of $5.51.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Monday, March 9th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.The firm had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.12 million.

Institutional Investors Weigh In On Lipocine

A number of institutional investors have recently made changes to their positions in LPCN. Citadel Advisors LLC acquired a new position in shares of Lipocine in the third quarter valued at approximately $41,000. Geode Capital Management LLC lifted its holdings in Lipocine by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after purchasing an additional 1,374 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Lipocine by 3.6% in the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 1,300 shares during the period. Jane Street Group LLC bought a new stake in Lipocine in the 4th quarter valued at $85,000. Finally, Persistent Asset Partners Ltd acquired a new position in Lipocine in the 4th quarter valued at $567,000. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.